In preclinical models, different studies have shown that anti–CTLA-4 increases the intratumoral CD8+/T reg cell and T eff/T reg cell ratios, promoving preferential depletion of T reg cells at the tumor site (128–130). Here, CTLA4 is linked to neoplasm.